Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Second meningococcal booster vaccination in Dutch children: MenACWY-TT versus MenC-TT
NL-OMON19891Phase 4Active, not recruiting
- Sponsor
- National Institute for Public Health and the Environment
- Start
- Mar 2014
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of Meningococcal polysaccharide vaccine group W-135 and Meningococcal group C polysaccharide conjugate vaccine in meningococcal disease (2 arms), sponsored by National Institute for Public Health and the Environment. Primary endpoints: MenC serum bactericidal antibody non-inferiority at 1 year and Age-group comparison of MenA, MenW, and MenY serum bactericidal antibodies at 1 year. Started Mar 2014; status: active, not recruiting.
02
Drugs
Meningococcal polysaccharide vaccine group W-135Meningococcal group C polysaccharide conjugate vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on NL-OMON19891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON19891.